Halozyme CEO Helen Torley poses in front of the company’s San Diego office. The biotech recently inked another deal with pharmaceutical giant Roche. File photo by Jamie Scott Lytle

Halozyme CEO Helen Torley poses in front of the company’s San Diego office. The biotech recently inked another deal with pharmaceutical giant Roche. File photo by Jamie Scott Lytle

Halozyme, Inc.

CEO: Helen Torley

2017 Revenue: $316.6 million

Headquarters: Sorrento Valley

Number of employees: 255

Stock: HALO on Nasdaq

Description: The company makes a successful drug delivery platform, and it’s in final clinical trials with a cancer drug.

Halozyme Therapeutics is expanding the reach of its platform that delivers drugs under the skin, intended to do away with lengthy infusions...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129